How Strategic Protocol Optimization Can Maximize Success for Biotechs
How Strategic Protocol Optimization Can Maximize Success for Biotechs
Sponsored by:
Sponsored by:
More from R&D
• By
The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.
• By
Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.
• By
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
• By
After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.
More from Scrip
Sponsored by:
Learn how advances in vaccine adjuvants are shaping the future of global health and driving more effective immunization strategies
Sponsored by:
Learn how advances in vaccine adjuvants are shaping the future of global health and driving more effective immunization strategies
Sponsored by:
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Sponsored by:
Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG